• Company entered DOCA with Biortica in April 2024
• Executed binding agreement to acquire Biortica (backdoor listing)
• Sold rights to 3 intellectual properties for $125,000 and debt forgiveness
• Profit of $258,977 vs prior year loss of $6.4 million
• Revenue up 70% to $1.48 million, driven by 143% increase in medical cannabis sales

BOD Science Limited (the Company) entered into a Deed of Company Arrangement (DOCA) with Biortica in April 2024, with Andrew Barnden appointed as Deed Administrator. The Company continues to trade under the DOCA and its securities remain suspended. In November 2024, the Company executed a binding conditional Share Purchase Agreement to acquire all the shares in Biortica, in consideration for the issue of ordinary shares in the Company (a backdoor listing). Also in November 2024, the Company executed and completed an asset sale deed, selling its rights to three intellectual properties, including soft gel/Schedule 3 clinical research and data, Aqua Phase, and CLIC Protein IP, to Optimus Salvus Limited for $125,000 and the forgiveness of a £2,000,000 debt claimed by the Aqua Phase inventors. The profit for the consolidated entity after providing for income tax amounted to $258,977, compared to the previous corresponding period (PCP) loss of $6,412,941. Total revenue for the year was $1,484,835, a 70% increase on the PCP (2024: $875,559). Sales revenue from the consolidated entity's Bod Flora, FGW and MediCabilis® medicinal cannabis product ranges in Australia and the UK was $1,484,835, a 143% increase on the PCP (2024: $610,061). The consolidated entity launched its first Tetrahydrocannabinol (THC) product in Australia in December 2023 and has subsequently launched a further 11 THC products. THC sales of $1,081,718 represented 73% of Medical sales during the year (2024: $224,590, 37%) and these SKUs are driving the sales growth of the business. The consolidated entity's gross profit margin was 23% compared to 30% for the prior year, due to the exit from the higher margin over the counter, legacy health and beauty business and discounting in the Medical business to clear slow-moving inventory.